Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Familial Hypercolerstremia as Risk Factor in Stemi Patient Who Underwent Ppci

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03900169
Recruitment Status : Not yet recruiting
First Posted : April 2, 2019
Last Update Posted : April 9, 2019
Sponsor:
Information provided by (Responsible Party):
Amira Harby, Assiut University

Brief Summary:
Famulial hypercolerstremia as risk factor

Condition or disease Intervention/treatment
Familial Hypercholesterolemia Genetic: Genetic

Detailed Description:
Familial hypercolerestremia ad risk factor in stemi patient who underwent Ppci

Layout table for study information
Study Type : Observational
Estimated Enrollment : 2 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Familial Hypercoleresremia as Risk Factor in Stemi Patient Underwent Ppci
Estimated Study Start Date : June 1, 2019
Estimated Primary Completion Date : June 1, 2019
Estimated Study Completion Date : June 1, 2020

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Stemi patient
Stemi patient who underwent Ppci
Genetic: Genetic
Lipid profile




Primary Outcome Measures :
  1. Correlation between familial hypercolerstremia and prognosis of patients in PPCI [ Time Frame: One year ]
    Correlation between familial hypercolerstremia and prognosis of patients in PPCI

  2. Correlation between non familial hypercolerstremia and prognosis of patients in PPCI [ Time Frame: One year ]
    Correlation between non familial hypercolerstremia and prognosis of patients in PPCI



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
Stemi patient
Criteria

Inclusion Criteria:

-all patient that underwent Ppci

Exclusion Criteria:

  • Previous ischemic patient
  • Patient with raised renal chemistry
  • Patient for CABG

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03900169


Contacts
Layout table for location contacts
Contact: Amira Abde naiem 01098503792 docmero93@.com
Contact: Ahmad Abdel gelel 01005015156 ahmed_gelil@yahoo.com

Locations
Layout table for location information
Egypt
Amira harby Recruiting
Assiut, Egypt
Contact: Amira Abdel naiem    01098503792      
Sponsors and Collaborators
Assiut University

Layout table for additonal information
Responsible Party: Amira Harby, Principle investigator, Assiut University
ClinicalTrials.gov Identifier: NCT03900169     History of Changes
Other Study ID Numbers: Familial hypercolerstremia
First Posted: April 2, 2019    Key Record Dates
Last Update Posted: April 9, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hyperlipoproteinemia Type II
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Hyperlipoproteinemias